Citations

Clear

1526 citation(s) found for "Sun, Yu".

A Systematic Review of Noninvasive Electrocardiogram Monitoring Devices for the Evaluation of Suspected Cardiovascular Syncope
Trombetta, Lucia, Erba, Luca , Bozzano, Viviana , Barbic, Franca , Casazza, Giovanni , Dipaola, Franca , Furlan, Raffaello , Kenny, Rose Anne , Quinn, James , Sheldon, Robert S. , Shen, Win-Kuang, Sun, Benjamin , Thiruganasambandamoorthy, Venkatesh , Reed, Matthew J. , Solbiati, Monica , Sacco, Roberto M., Costantino, Giorgio , Raj, Satish R , Thiruganasambandamoorthy, Venkatesh , Kenny, Rose Anne , Dipaola, Franca , Furlan, Raffaello

Mayo Clinic

Journal of Medical Devices | February 8, 2019 | Volume: 13 | Issue: 2 | Pages: No page available

10.1115/1.4042795 Get It

The aims of this study were (1) to identify research publications studying noninvasive electrocardiogram (ECG) monitoring devices, (2) to define and categorize current technology in noninvasive ECG recording, and (3) to discuss desirable noninvasive recording features for personalized syncope evaluation to guide technological advancement and future studies. We performed a systematic review of the literature that assessed noninvasive ECG-monitoring devices, regardless of the reason for monitoring. We performed an Internet search and corresponded with syncope experts and companies to help identify further eligible products. We extracted information about included studies and device features. We found 173 relevant papers. The main reasons for ECG monitoring were atrial fibrillation (n = 45), coronary artery disease (n = 10), syncope (n = 8), palpitations (n = 8), other cardiac diseases (n = 67), and technological aspects of monitoring (n = 35). We identified 198 devices: 5 hospital telemetry devices, 12 patches, 46 event recorders, 70 Holter monitors, 23 external loop recorders, 20 mobile cardiac outpatient telemetries, and 22 multifunctional devices. The features of each device were very heterogeneous. There are a large number of ECG-monitoring devices with different features available in the market. Our findings may help clinicians select the appropriate device for their patients. Since there are only a few published articles analyzing their usefulness in syncope patients, further research might improve their use in this clinical setting.
Reactive capillary hemangiomas induced by camrelizumab (SHR-1210), an anti-PD-1 agent
Guo, Ruifeng , Sun, Jianfang , Jiang, Yiqun , Guo, Ruifeng , Teng, Yan, Liu, Yi

Mayo Clinic

Acta Oncologica | January 31, 2019 | Volume: 58 | Issue: 3 | Pages: 388-389

10.1080/0284186x.2019.1567935 | PMID 30700195 Get It

Characteristics and proposed classification system of posterior pilon fractures
Zhang, Jianzheng , Pen, Cheng, Qu, Wen-chun, Duan, Lida, Ren, Jixin, Qu, Wenchun , Wang, Hao , Li, Lianhua , Liu, Zhi , Sun, Tiansheng

Mayo Clinic

Medicine | January 17, 2019 | Volume: 98 | Issue: 3 | Pages: e14133

10.1097/md.0000000000014133 | PMID 30653144 Get It

Abstract Posterior pilon fractures involve the medial malleolus (MM). Our purpose was to define the characteristics of posterior pilon fractures, and propose a classification system based on fracture morphology and type of management. The records of patients with posterior pilon fractures treated from 2011 to 2015 were retrospectively reviewed. The injury mechanism, fracture morphology, surgical approach, and follow-up results were reviewed and analyzed. This study was approved by the Institutional Review Board of PLA Army General Hospital. Thirty-six patients, 18 males and 18 females (mean age: 48.9 years) were included in the study. Four characteristics were used to define posterior pilon fractures. A simple posterolateral approach or a combined posterolateral and posteromedial approach was used for reduction and fixation in all patients. The mean follow-up time was 28.2 months, and at the end of follow-up, the mean American Orthopedic Foot and Ankle Society Score (AOFAS) was 82.5 points (range: 35–100 points). Based on injury mechanism and fracture morphology, we classified posterior pilon fractures into 3 types that suggest the optimal surgical approach: type I, a single complete fracture fragment; type II, a posterior malleolus fracture with 2 subtypes; type III, a posterior malleolus fracture associated with complete MM fracture with 2 subtypes. The proposed classification system based on injury mechanism and fracture morphology can guide the surgical approach to maximize outcomes.
Book-Shaped Acellular Fibrocartilage Scaffold with Cell-loading Capability and Chondrogenic Inducibility for Tissue-Engineered Fibrocartilage and Bone–Tendon Healing
Chen, Can , Liu, Fei , Tang, Yifu , Zheng, Cheng , Chen, Yang , Li, Muzhi , Zhao, Chunfeng , Sun, Lun‐Quan , Lü, Hongbin , Zheng, Cheng , Chen, Yang , Li, Muzhi , Lu, Hongbin , Qu, Jin , Cao, Yong Bing , Hu, Jianzhong

Mayo Clinic

ACS Applied Materials & Interfaces | January 9, 2019 | Volume: 11 | Issue: 3 | Pages: 2891-2907

10.1021/acsami.8b20563 | PMID 30620556 Get It

Pain-induced peripheral artery tonometry scores in the control arm are impaired in patients with apical ballooning syndrome
Sun, Tao , Matsuzawa, Yasushi , Lennon, Ryan J. , Park, Kyoung H., Lerman, Lilach O. , Widmer, R. Jay , Lennon, Ryan J. , Lerman, Amir

Mayo Clinic

Medicine | January 4, 2019 | Volume: 98 | Issue: 1 | Pages: e13841

10.1097/md.0000000000013841 | PMID 30608400 Get It

Abstract Mental and physical stress is thought to play an important causative factor in apical ballooning syndrome (ABS) likely secondary to the vasomotor dysfunction. However, there are currently few data related to the impact of physical stress in this unique cardiomyopathy. A total 18 patients, including 8 females with history of ABS and 10 post-menopausal controls, underwent physical and mental tests. Assessments included the pain-induced peripheral artery tonometry scores (PIPATs) and mental stress peripheral artery tonometry scores (PATs). Compared with control group, PIPATs were significantly attenuated in patients with ABS in both baseline and post-mental stress (0.94 ± 0.08 vs1.30 ± 0.54, P <.05 and 0.87 ± 0.19 vs1.24 ± 0.21 P = .01, respectively); mental stress PATs were significantly lower in patients with ABS, both in Stroop test (0.79 ± 0.30 vs 1.24 ± 0.43, P = .01) and arithmetic test (0.91 ± 0.27 vs 1.36 ± 0.57, P = .01). PIPATs correlated significantly with mental stress PATs, both in arithmetic and Stroop test (P <.05). The PIPATs were attenuated in female with history of ABS and the vascular response to pain may provide a different pathogenesis mechanism on detecting patients with ABS.
Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer.
Han, Leona C., Shah, Nilay D. , Gross, Cary P. , Smaldone, Marc C., Tilburt, Jon C. , Trinh, Q.D., Karnes, R. Jeffrey , Ranasinghe, Weranja Kalana Bodhisiri, Sun, Maxine , Kim, Simon P. , Ranasinghe, Weranja , Ross, Joseph S. , Nguyen, Paul L. , Yu, James B.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16085-e16085

10.1200/jco.2014.32.15_suppl.e16085 Get It

Out-of-pockets costs for patients receiving targeted agents for metastatic renal cell carcinoma.
Kim, Simon P. , Gross, Cary P. , Abouassaly, Robert , Houten, Holly K. Van , Thompson, R. Houston, Smaldone, Marc C., Trinh, Q.D., Sun, Maxine , Han, Leona C., Shah, Nilay D. , Psutka, Sarah P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e15598-e15598

10.1200/jco.2014.32.15_suppl.e15598 Get It

Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series
Rowland, Kendrith M. , Atherton, Pamela J., Dakhil, Christopher, Sun, Zhifu , Tan, Angelina D., Schmidt, Lucy J., Nguyen, Phuong L., Breitkopf, Carmen Radecki , Pittelkow, Mark R. , Tindall, Donald J., Menon, Smitha, Jatoi, Aminah , Atherton, Philip J. , Tan, Angelina, Schmidt, Lucy, Tindall, Donald, Jatoi, Aminah , Sun, Zhifu , Le‐Rademacher, Jennifer , Atherton, Pamela J., Atherton, Philip J.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | January 3, 2019 | Volume: 36 | Issue: 6 | Pages: 519-525

10.1177/1049909118819820 | PMID 30602311 Get It

Background: Although 50% to 90% of patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash, options for rash prevention or palliation remain limited. This issue is particularly important from a palliative care standpoint because these agents are prescribed only to patients with incurable cancer. Here, we report (1) gene expression profiling of skin biopsies from patients with an EGFR inhibitor–induced rash and (2) a randomized, placebo-controlled feasibility trial with the antiandrogen, spironolactone. Both investigations were undertaken to begin to explore the hypothesis that androgens mediate EGFR inhibitor–induced rash and that antiandrogens palliate it. Methods/Results: First, 4 skin biopsies from patients with EGFR inhibitor–induced rash (3 men and 1 woman) were subject to gene expression microarray profiling. A public data set of normal skin gene expression (Gene Expression Omnibus, GSE22998) served as a reference. Sixty percent of commonly interrogated androgen receptor genes (207 of 308 between the 2 data sets) were differentially expressed ( P < .05) in the rash samples. Second, in a 17-patient double-blinded, placebo-controlled trial with topical spironolactone applied to the face, although the primary feasibility end point was not achieved, patients in the spironolactone arm received more doses of EGFR inhibitor, and anecdotal photographic evidence suggested salutatory effects of spironolactone on rash. Conclusions: Epidermal growth factor receptor inhibitor–induced rash appears to be androgen-mediated; antiandrogen therapy merits further study for rash prevention/palliation.
KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—Asian subgroup analysis.
Muro, Kei , Fuchs, Charles S. , Jang, Raymond Woo-Jun, Sun, Weijing , Jalal, Shadia I. , Golan, Talia , Mandalà, Mario , Catenacci, Daniel V.T. , Lin, Jianxin, Yoon, Harry H. , Doi, Toshihiko , Satoh, Taroh , Machado, Manuela , Shah, Manish A , Metges, Jean‐Philippe , Garrido, Marcelo , Wainberg, Zev A. , Bang, Yung‐Jue , Lu, Jia

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 723-723

10.1200/jco.2018.36.4_suppl.723 Get It

723 Background: The US FDA approved pembro for treating pts with 1) recurrent locally advanced or metastatic G/GEJ adenocarcinoma, whose disease has progressed on or after ≥2 prior therapies and whose tumors express PD-L1 (combined positive score [CPS] ≥1), and 2) unresectable or metastatic, microsatellite instability-high (MSI-H) solid tumors that have progressed after prior therapy and who have no fitting options. We report Asian subgroup analyses from cohort 1 of KEYNOTE-059 (NCT02335411), a global, phase 2 study in advanced G/GEJ cancer. Methods: Eligible pts had measurable recurrent or metastatic G/GEJ adenocarcinoma whose disease has progressed on ≥2 prior chemotherapy regimens. Pts received pembro 200 mg Q3W up to 2 y. PD-L1+ tumors had a CPS ≥1. Primary end points were ORR (RECIST 1.1, by central review) and safety. Results: Cohort 1 enrolled 259 pts; 57% had PD-L1+ tumors. MSI status was evaluable in 174 tumor samples; of these, 7 were MSI-H. At data cutoff (4/21/2017), median (range) follow-up was 6 mo (1-25). Overall ORR was 12% (95% CI, 8-17) and median (range) DOR was 14 mo (2-19+). PFS6-mo rate was 15% and OS6-mo rate was 46%. In pts with PD-L1+ tumors, ORR was 16% (95% CI, 11-23) and median (range) DOR was 14 mo (3+-19+). In pts with PD-L1+ tumors, PFS6-mo rate was 20% and OS6-mo rate was 50%. In pts with MSI-H tumors, ORR was 57% (95% CI, 18-90) and median (range) DOR was not reached (5-14+ mo). In cohort 1, 41 pts were Asian and 218 pts were non-Asian. PD-L1+ tumors occurred in 42% of Asian pts and 60% of non-Asian pts. ORR was 12% (95% CI, 2-36) in Asian pts with PD-L1+ tumors and 17% (95% CI, 11-24) in non-Asian pts with PD-L1+ tumors. One of 7 pts with MSI-H tumors was Asian; this pt had CR. Grade 3-5 treatment-related AEs occurred in 17% and 18% of Asian and non-Asian pts, similar to the overall cohort. Conclusions: Pembro showed durable clinical benefit in previously treated pts with advanced G/GEJ cancer, especially those with PD-L1+ or MSI-H tumors. Safety and efficacy were similar in Asian and non-Asian pts. These findings highlight pembro as a standard treatment option in Asian and non-Asian pts with advanced G/GEJ cancer. Clinical trial information: NCT02335411.